Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2871 - 68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma and salivary duct carcinoma

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Staging and Imaging

Tumour Site

Head and Neck Cancers

Presenters

Wim van Boxtel

Citation

Annals of Oncology (2018) 29 (suppl_8): viii479-viii482. 10.1093/annonc/mdy294

Authors

W. van Boxtel1, S. Lütje2, I. van Engen-van Grunsven3, G. Verhaegh4, J. Schalken4, M. Janssen2, J. Nagarajah2, M. Gotthardt2, C.M.L. van Herpen5

Author affiliations

  • 1 Medical Oncology, Radboud university medical center, 6525AG - Nijmegen/NL
  • 2 Radiology And Nuclear Medicine, Radboud university medical center, 6525AG - Nijmegen/NL
  • 3 Pathology, Radboud university medical center, 6525AG - Nijmegen/NL
  • 4 Urology, Radboud university medical center, 6500 HB - Nijmegen/NL
  • 5 Medical Oncology, Radboud University Medical Centre Nijmegen, 6525AG - Nijmegen/NL
More

Resources

Abstract 2871

Background

Salivary gland cancer (SGC) is a rare cancer with few treatment options. Adenoid cystic carcinoma (ACC) and salivary duct carcinoma (SDC) are major subtypes of SGC which often show immunohistochemical expression of prostate-specific membrane antigen (PSMA). In prostate cancer, PSMA ligands labeled with radioisotopes such as 68Ga or 177Lu, are used for imaging or therapy. The aim of this study was to evaluate 68Ga-PSMA ligand uptake in patients with locally recurrent and/or metastatic ACC and SDC and to establish the diagnostic value of 68Ga-PSMA-PET/CT imaging compared to full-dose CT imaging.

Methods

68Ga-PSMA-HBED-CC PET/CT scans were performed in 14 ACC patients and 10 SDC patients including a full-dose CT scan of the neck, chest and abdomen. 68Ga-PSMA ligand uptake was evaluated in local recurrences and metastatic lesions. Detected lesions were compared to CT results. Maximum standardized uptake values (SUVmax) were determined. The study protocol was approved by the local medical ethical committee and a written informed consent was obtained from all patients.

Results

Moderate to intense PSMA ligand uptake was observed in local recurrences and distant metastases in all ACC patients and 40% of SDC patients. In addition, PSMA-PET imaging detected additional bone metastases in 2 ACC patients and additional lymph node metastases in 1 ACC patient which were not detected on a full-dose CT scan. In 1 ACC patient a local recurrence of a vulvar ACC was suspected on CT but PSMA-PET imaging was negative, which turned out to be scar tissue, eventually.

Conclusions

PSMA-PET imaging showed moderate to intense ligand uptake in local recurrences and distant metastases of all ACC patients and 40% of SDC patients. Based on the high uptake, these patients may be promising candidates for 177Lu-PSMA radioligand therapy in future. Moreover, PSMA-PET imaging has added diagnostic value compared to full-dose CT imaging.

Clinical trial identification

NCT03319641.

Legal entity responsible for the study

Radboud university medical center, Nijmegen, the Netherlands.

Funding

Adenoid Cystic Carcinoma Research Foundation (ACCRF) and the Dutch Salivary Gland Cancer Patient Platform.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.